Ocugen

Ocugen OCGN Stock

$0.77   4.789845%
Add to favorites
Market Cap
$260.55M
LOW - HIGH [24H]
$0.71 - $0.82
VOLUME [24H]
$6.19M
P/E Ratio
0
Earnings per share
-$0.20
ISIN
US67577C1053
Price   Prediction

Ocugen Price Chart

Sorry, that's all we've gotfor now...

Ocugen (OCGN) stock price today is 0.77 USD on Tech Market Small (+4.79% on the day). Updated .

Ocugen OCGN Financial and Trading Overview

Ocugen stock price 0.77 USD
Previous Close 0.74 USD
Open 0.74 USD
Bid 0.64 USD x 100
Ask 0.84 USD x 100
Day's Range 0.72 - 0.75 USD
52 Week Range 0.69 - 2.73 USD
Volume 9.34M USD
Avg. Volume 7.2M USD
Market Cap 248.64M USD
Beta (5Y Monthly) 1.982
PE Ratio (TTM) N/A
EPS (TTM) -0.2 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 12.17 USD

OCGN Valuation Measures

Enterprise Value 252.95M USD
Trailing P/E N/A
Forward P/E -4.071111
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 52.017548
Price/Book (mrq) N/A
Enterprise Value/Revenue 52.918
Enterprise Value/EBITDA -3.736

Trading Information

Ocugen Stock Price History

Beta (5Y Monthly) 1.982
52-Week Change -33.42%
S&P500 52-Week Change 12.00%
52 Week High 2.73 USD
52 Week Low 0.69 USD
50-Day Moving Average 0.91 USD
200-Day Moving Average 1.38 USD

OCGN Share Statistics

Avg. Volume (3 month) 7.2M USD
Avg. Daily Volume (10-Days) 7.96M USD
Shares Outstanding 339.31M
Float 334.5M
Short Ratio 15.88
% Held by Insiders 1.40%
% Held by Institutions 44.34%
Shares Short 107.67M
Short % of Float 31.73%
Short % of Shares Outstanding 31.73%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:60

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -1444.14%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -52.088%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 4.78M USD
Revenue Per Share (ttm) 0.02 USD
Quarterly Revenue Growth (yoy) 11.40%
Gross Profit (ttm) -40334000 USD
EBITDA -67703000 USD
Net Income Avi to Common (ttm) -65359000 USD
Diluted EPS (ttm) -0.2
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 84.26M USD
Total Cash Per Share (mrq) 0.25 USD
Total Debt (mrq) 88.56M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.769
Book Value Per Share (mrq) -0.052

Cash Flow Statement

Operating Cash Flow (ttm) -63692000 USD
Levered Free Cash Flow (ttm) -21493000 USD

Profile of Ocugen

Country United States
State PA
City Malvern
Address 11 Great Valley Parkway
ZIP 19355
Phone 484 328 4701
Website https://www.ocugen.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 116

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Q&A For Ocugen Stock

What is a current OCGN stock price?

Ocugen OCGN stock price today per share is 0.77 USD.

How to purchase Ocugen stock?

You can buy OCGN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ocugen?

The stock symbol or ticker of Ocugen is OCGN.

Which industry does the Ocugen company belong to?

The Ocugen industry is Biotechnology.

How many shares does Ocugen have in circulation?

The max supply of Ocugen shares is 339.31M.

What is Ocugen Price to Earnings Ratio (PE Ratio)?

Ocugen PE Ratio is now.

What was Ocugen earnings per share over the trailing 12 months (TTM)?

Ocugen EPS is -0.2 USD over the trailing 12 months.

Which sector does the Ocugen company belong to?

The Ocugen sector is Healthcare.

Ocugen OCGN included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us US Tech Capital Market Composite RCMP US 100.96 USD —
-4.6
— — 100.89 USD — 105.64 USD — — — —
$2.04T
Total marketcap
$118.95B
Total volume
BTC 57.75%   •   ETH 9.66%
Dominance
Select currency